{"id":381553,"date":"2020-11-16T08:03:17","date_gmt":"2020-11-16T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381553"},"modified":"2020-11-16T08:03:17","modified_gmt":"2020-11-16T13:03:17","slug":"receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/","title":{"rendered":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SEATTLE, Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA).<\/p>\n<p>The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or otherwise work with Schedule I controlled substances. Under the license, Receptor will research the application of its drug delivery technologies to selected Schedule 1 drugs. This work is ultimately directed to development of prescription therapies to treat a variety of central nervous system disorders.<\/p>\n<p>\u201cThis license is an exciting milestone on our path to identifying safe and effective therapies,\u201d said Greg Wesner, CEO, Receptor Life Sciences. \u201cWe\u2019re proud to be a leader in the research and development of cannabinoid prescription medications to treat central nervous system disease.\u201d<\/p>\n<p>\n        <strong>About Receptor Life Sciences<\/strong><br \/>\n        <br \/>Receptor Life Sciences is a biotechnology company integrating proven drug delivery technologies and cannabinoid drug candidates to develop innovative medicines for the treatment of selected central nervous system diseases.<\/p>\n<p>The delivery technologies are validated by their use in FDA-approved oral and inhaled prescription drug products. Receptor\u2019s patented product candidates have the potential to provide prescription treatments for a range of unmet medical needs in central nervous system indications.<\/p>\n<p>More information is at <a href=\"http:\/\/www.ReceptorLife.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ReceptorLife.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:1822.5px;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:4%;width:71.7578px;min-width:4%\">Contact:<\/td>\n<td style=\"max-width:96%;width:1746.76px;min-width:96%\">David Sheon<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <a href=\"mailto:dsheon@whitecoatstrategies.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dsheon@whitecoatstrategies.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>202 422-6999<\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ea3a986c-9bdc-4814-9287-119f2de3aba1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or otherwise work with Schedule I controlled substances. Under the license, Receptor will research the application of its drug delivery technologies to selected Schedule 1 drugs. This work is ultimately directed to development of prescription therapies to treat a variety of central nervous system disorders. \u201cThis license is an exciting milestone on our path to identifying safe and effective therapies,\u201d said Greg Wesner, CEO, Receptor Life Sciences. \u201cWe\u2019re proud to be a leader &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381553","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or otherwise work with Schedule I controlled substances. Under the license, Receptor will research the application of its drug delivery technologies to selected Schedule 1 drugs. This work is ultimately directed to development of prescription therapies to treat a variety of central nervous system disorders. \u201cThis license is an exciting milestone on our path to identifying safe and effective therapies,\u201d said Greg Wesner, CEO, Receptor Life Sciences. \u201cWe\u2019re proud to be a leader &hellip; Continue reading &quot;Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency\",\"datePublished\":\"2020-11-16T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/\"},\"wordCount\":234,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/\",\"name\":\"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\",\"datePublished\":\"2020-11-16T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/","og_locale":"en_US","og_type":"article","og_title":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk","og_description":"SEATTLE, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or otherwise work with Schedule I controlled substances. Under the license, Receptor will research the application of its drug delivery technologies to selected Schedule 1 drugs. This work is ultimately directed to development of prescription therapies to treat a variety of central nervous system disorders. \u201cThis license is an exciting milestone on our path to identifying safe and effective therapies,\u201d said Greg Wesner, CEO, Receptor Life Sciences. \u201cWe\u2019re proud to be a leader &hellip; Continue reading \"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency","datePublished":"2020-11-16T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/"},"wordCount":234,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/","name":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==","datePublished":"2020-11-16T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjAxMyMzODI3MDE0IzUwMDA2NTQ3MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/receptor-life-sciences-receives-schedule-i-research-license-from-u-s-drug-enforcement-agency\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381553"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}